Incretin-based therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, have been more recently indicated as promising insulin-sensitizing therapeutic options for PCOS. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.